Nice find. So their next study is going to address the safety concerns?

I think it was a mistake to have that arm that combined this drug with memantine. Memantine doesn't work all that well and has side effects of its own, and trying a new drug in combination with it -- which may have some kind of horrible interaction -- seems like a mistake.

It looks like this vTv company is not publicly traded. Is that correct?

Also -- for anyone wondering, it's perfectly fine to talk about Alzheimers' research companies other than AVXL. Our rules here about discussing other companies are much looser than other message boards.